Stock APLS APELLIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
48.7 USD +2.23% Intraday chart for Apellis Pharmaceuticals, Inc. -6.02% -18.64%
Apr. 17 Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating MT
Apr. 09 Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing MT

Evolution of the average Target Price on Apellis Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

465e1f74861b0137cd245dd3.N5m6IBinfbmTjkSjO_LiRZAIb3847qD1O6EdbINm5AA.U7TuE2jLL4jFzCbFXZjQfOQ_AQ8V3OqPVeVoOsA201lSq_dUYNQU0N7PdA~0b9da5942584d4c316fabc0c724044b3

Analyst Recommendations on Apellis Pharmaceuticals, Inc.

Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing MT
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating MT
Wedbush Raises Apellis Pharmaceuticals' PT to $67 From $60, Keeps Neutral Rating; Says Awaiting Further Clarity on Potential EU Regulatory Path for Syfovre MT
Mizuho Raises PT on Apellis Pharmaceuticals to $60 From $49 Ahead of Q4 2023 Earnings Announcement, Keeps Neutral Rating MT
UBS Adjusts Apellis Pharmaceuticals Price Target to $87 From $70, Maintains Buy Rating MT
North American Morning Briefing : Rate Doubts Keep -2- DJ
Jefferies Upgrades Apellis Pharmaceuticals to Buy From Hold, Adjusts Price Target to $80 From $68 MT
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $79 From $75, Maintains Outperform Rating MT
Needham Adjusts Price Target on Apellis Pharmaceuticals to $75 From $70, Maintains Buy Rating MT
Wells Fargo Raises Apellis Pharmaceuticals' Price Target to $62 From $54, Maintains Equalweight Rating MT
Baird Adjusts Apellis Pharmaceuticals' Price Target to $81 From $71, Maintains Outperform Rating MT
Raymond James Adjusts Apellis Pharmaceuticals' Price Target to $106 From $67, Maintains Strong Buy Rating MT
Goldman Sachs Adjusts Price Target on Apellis Pharmaceuticals to $90 From $65, Maintains Buy Rating MT
Citigroup Adjusts Apellis Pharmaceuticals' Price Target to $67 From $70, Maintains Buy Rating MT
Oppenheimer Cuts Apellis Pharmaceuticals Price Target to $75 From $88, Maintains Outperform Rating MT
Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $67 From $93, Keeps Strong Buy Rating MT
Needham Adjusts Apellis Pharmaceuticals' Price Target to $56 From $63, Keeps Buy Rating MT
Wedbush Adjusts Apellis Pharmaceuticals Price Target to $39 From $44, Maintains Neutral Rating MT
Wells Fargo Downgrades Apellis Pharmaceuticals to Equalweight From Overweight, Cuts Price Target to $54 From $67 MT
Apellis Pharmaceuticals' Syfovre Label Update Reflects 'Confidence' From US FDA, BofA Says; Rating, Price Objective Raised MT
BofA Upgrades Apellis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $85 From $52 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
47.64 USD
Average target price
82.01 USD
Spread / Average Target
+72.15%
High Price Target
110 USD
Spread / Highest target
+130.90%
Low Price Target
57 USD
Spread / Lowest Target
+19.65%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Apellis Pharmaceuticals, Inc.

Wedbush
JPMorgan Chase
UBS
Mizuho Securities
Jefferies & Co.
Oppenheimer
Needham & Co.
Wells Fargo Securities
Baird
Raymond James
Goldman Sachs
Citigroup
BofA Securities
Stifel Nicolaus
HC Wainwright
Credit Suisse
Roth Capital Partners
BMO Capital
Cowen
J.P. Morgan Chase

Ratings for Apellis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. APLS Stock
  4. Consensus Apellis Pharmaceuticals, Inc.